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Abstract: Over the past century, advances in biomedical 
technologies have resulted in a need for government 
regulation of the distribution of genetic modification and 
medical enhancements. Without these regulations, the poor 
of Appalachia will suffer immensely from the lack of 
protection against genetic diseases, and disorders, and 
lack of opportunity for genetic enhancements, and will 
eventually fall further behind more developed and wealthy 
areas regarding their health and quality of life. She 
suggests that government regulations such as implementing 
systems focused around utilitarianism, prioritarianism, and 
equality could help to reverse this effect of poverty and 
unequal distribution of health. 
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The Appalachian Dilemma: An Ethical Debate on Genetic 
Therapy and Genetic Enhancement 
 
     In the past century, advances in biomedical 
technologies have increased exponentially and are projected 
to maintain that trend in the future. With any new 
technology comes new issues that have to be resolved. For 
example, genetic engineering of crops has the potential to 
increase agricultural productivity, however, it poses very 
serious environmental risks that must be considered 
(Altieri, 2000). In the same way, biomedical technology 
brings with it new medical procedures, and with new medical 
procedures comes a great deal of biomedical ethical 
disputes that then spread throughout the biotechnical and 
biomedical communities. One highly debated matter within 
the biomedical community surrounds the just distribution of 
healthcare. 
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     In America, this matter centers itself around the 
impoverished of the country—or those who cannot pay for 
medical services as readily as the wealthier classes.  
Appalachia is known for many things, a few being the lack 
of education and the abundance of poverty within the region 
over a very long span of time. Therefore, this lack of 
wealth results in an absence of proper health care. 
Appalachia falls behind in many rankings. “In [Appalachian 
settlements], in which virtually everyone [is] at risk of 
poor health outcomes…” individuals wonder why some families 
have incredibly sick children and other do not. It boils 
down to the wealth and education of the parents of those 
children (Erwin, 2008).  
     With new biomedical technologies and procedures, the 
ability to prevent genetic diseases and disorders and 
genetically enhance offspring has become possible (Sankar, 
2015). With the effects of poverty in Appalachia, the 
ability for individuals to receive this treatment would be 
minimal if treatment is given only to those who have the 
means to pay for it on their own without the help of health 
insurance coverage. Government regulations such as 
implementing systems focused around utilitarianism, 
prioritarianism, and equality could help to reverse this 
effect of poverty with the just distribution of health 
 
 
3 
care, but the principles of biomedical ethics must 
contribute to the making of any policies or allocation 
system. Otherwise, the three ethical topics must all 
promote each other equally which can only happen in certain 
situations. Without proper ethical policy to regulate the 
usage and distribution of new genetic biomedical 
technologies, the poor of Appalachia will suffer immensely 
from the lack of protection against genetic diseases and 
the lack of opportunity for enhancements past a basic 
healthcare need.  
           
The CRISPR-Cas9 System: A Solution 
     Thanks to biomedical technology and advances in 
biomedical sciences, it is commonly known that every cell 
in the human body has a copy of that individual’s genome. 
Advances in genetic sequencing have allowed researchers to 
make connections between the genome and a variety of 
diseases. After learning the major effect of the genome on 
a person’s health, scientists began looking for ways to 
safely alter the genome as a solution to these diseases. 
Although other solutions have been discovered, the CRISPR-
Cas9 system is the most inexpensive, effective, and 
therefore the most efficient method of altering the genome. 
Jeffry D. Sander and J. Keith Joung claim that even though 
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“the genome-wide specificities of CRISPR-Cas9 systems 
remain to be fully defined, the capabilities of these 
systems to perform targeted, highly efficient alterations 
of genome sequence and gene expression will undoubtedly 
transform biological research and spur the development of 
novel molecular therapeutics for human disease” (Sander, 
2014). The biomedical technology presents the ability to 
engineer biological systems and organisms and this has 
enormous potential for applications across science, 
medicine, and biotechnology (Ran, 2013). CRISPR technology, 
or clustered regularly interspaced short palindromic 
repeat, is an adaptable immune mechanism that is used in 
nature by bacteria to protect itself from viral infections 
and from plasmids, meaning it is not “new” technology in 
the sense, but is being applied in a new way. The 
development of this recombinant DNA technology began in the 
1970’s, but recent advances in the technologies have begun 
a sort of biotechnological revolution (Hsu, 2014). 
 
How Does It Work? 
What is the CRISPR-Cas9 system and what does it 
actually do? Simply, it can remove one piece of DNA and 
replace it with another piece. For example, if someone has 
a gene that makes them more susceptible to a certain 
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disease, the CRISPR-Cas9 system could cut that piece of DNA 
out of the genome, and insert a new and healthy gene in its 
place. Within the cell, the system is not much more 
complex. Clustered regularly interspaced short palindromic 
repeats or CRISPR, CRISPR Associated genes (Cas) and the 
Cas protein (Cas9) are the main factors in this technology 
(Scherz, 2017).  
To begin, the use of CRIPSR-Cas9 in nature must be 
discussed, and that involves the defense mechanism used by 
bacteria to protect itself against viral infection. To 
infect bacteria, viruses inject their DNA into the 
bacteria. To defend themselves from viral infection, 
bacteria use the CRISPR-Cas9 system to cut the viral 
deoxyribonucleic acid or DNA and hinder it mutated or 
nonfunctioning. The bacteria capture segments of DNA from 
invading viruses and use the sequences to create the DNA 
segments that are between the regularly-interspaced short 
palindromic repeats in CRISPR. The sequences used to 
identify viruses is a sort of archive of past attacks and 
is used to protect against attacks by those viruses again. 
Cas9, a CRISPR associated gene protein, is transcribed when 
virus DNA is detected, and it is an enzyme that acts as a 
pair of molecular scissors. This protein is targeted by 
guide ribonucleic acid or gRNA, also known as crRNA or 
 
 
6 
CRISPR RNA, and it then binds to the gRNA or crRNA that is 
produced from the CRISPR segments making the CRISPR-Cas9 
complex. The gRNA or crRNA binds to Cas9 and to the 
specific sequence in the DNA that has been selected for 
editing. The gRNA or crRNA has RNA bases that are 
complementary, by Wilson and Crick standards, to the bases 
of the target DNA sequence. The Virus DNA binds to the 
target sequence within the complex, and the DNA is pulled 
apart. Although the specific sequence within these crRNAs 
that targets DNA normally pairs to viral DNA, which is the 
natural mechanism for CRISPR-Cas9 antiviral defense in 
bacteria, the sequence can very easily be replaced by a 
sequence of interest to alter a specific piece of the 
genome. Then, Cas9 cuts the gene so that it is free from 
the rest of the sequence of DNA. When the two pieces of DNA 
are released, they try to come back together and mutations 
occur, disabling the gene altogether. Once the DNA is cut, 
researchers can use the cell’s own DNA repair machinery to 
add or delete pieces of genetic material, or replace the 
gene with a customized piece of DNA. (Reis, et. al, 2014).  
 
How will this be applied in healthcare treatments? 
     The clinical application of this technology has a few 
specificities. Treatment with the CRISPR-Cas9 therapy comes 
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in different forms. In most applications, the genetically 
modified cells are injected into the patient. The patient 
could either be an embryo still in development or could be 
a living individual. The injection could either effect the 
somatic cells of the patient, which would alter their 
genome in a way that was not then passed down to the 
patient’s offspring. On the other hand, the patient could 
be treated as an embryo or treated for cells that affect 
the reproductive organs of that individual, referred to as 
germline genome editing (Nicol, 2017). These new genetic 
modifications would be passed on to that individual’s 
offspring.  
 
Main Biomedical Ethical Issues 
     Although there are numerous biomedical ethical issues 
that need to be confronted, one of the most significant as 
of recent surrounds genetic modification technology. Eric 
Juengst’s  “Crowdsourcing the Moral Limits of Human Gene 
Editing?” confronts one of the most well-known and hot-
button ethical dilemmas of genetic modification. The 
dilemma is the ethical implications of “two kinds of 
potential gene-editing experiments in humans: those making 
inheritable germ-line modifications and those designed to 
enhance human traits beyond what is necessary for health 
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and healing” (Juengst, 2017). These two genetic 
modifications must be defined.  
 
Somatic vs. Germline 
The genetic modifications that are “making inheritable 
germ-line modifications” must be compared to the genetic 
modifications that do not (Jeungst). In the same way, 
genetic modification that is “designed to enhance human 
traits beyond what is necessary for health and healing” 
must be compared to genetic modification that is designed 
to treat for the patient’s health and healing.  
     Somatic-cell genetic enhancement includes genetic 
modification that introduces new, modified cells to 
nonreproductive cells. This would prevent them from being 
passed down to future generations. Germ-line genetic 
enhancement includes the introduction of genetically 
modified cells into reproductive cells, including the 
sperm, ova, or preimplantation embryos. The changes would 
then result in an alteration that is then passed down in 
the genome. (Degrazia, et.al, 2011) 
 
Therapy vs. Enhancement 
     Therapeutic genetic engineering, commonly called 
“genetic therapy,” includes interventions that are directed 
 
 
9 
at the cure of genetic disease. Nontherapeutic genetic 
engineering, or “genetic enhancement,” includes 
interventions directed towards the alteration and 
enhancement of human traits and capabilities such as 
height, strength, or intelligence. (Degrazia) 
 
Current Ethical Policy  
United States 
     Erwin dissects a consensus made by the United States’ 
National Academies of Science, Engineering, and Medicine 
(NASEM) in 2017 that can be described as ‘opening the door’ 
to the ethical conversation regarding genetic modification. 
In the end, they decided it was critical to allow diverse 
public input and voice in the policy-making process 
regarding the framework for ethical decision making in 
genetic enhancements and modification. Although this is a 
start to the discussion of biomedical ethical policy, still 
no actual action was taken to create a policy surrounding 
this major dilemma. It is imperative that this is one of 
the first ethical issues that has policy to regulate it. 
 
United Kingdom 
     In the United Kingdom, the Nuffield Council on 
Bioethics published a report of the ethical and social 
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implications raised by heritable genetic and genome editing 
treatments. They came to the conclusion in July of 2018 
that the use of genetic modification could be morally 
permissible in some circumstances. The recommendation given 
by the counsel was as follows:  
“Any use of genome editing interventions should be 
guided by two overarching principles: they must be 
intended to secure, and be consistent with, the 
welfare of the future person; and they should not 
increase disadvantage, discrimination, or division in 
society. More work needs to be done to establish 
whether these principles can be met. (Nuffield Council 
on Bioethics, 2018).” 
The council began to work on their report in September of 
2016.  
 
China 
 On the other hand, Chinese geneticists’ views of 
ethical issues are much different than that of geneticist 
in both America and the United Kingdom. China has made 
genetics a priority for decades. In the 1960’s, 
cytogenetics technology was introduced, and then in the 
1970’s, chronic villi sampling was performed (Mao). Now, 
reports have been made that a successful genetic 
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modification on an embryo has been performed in China. 
Because of the cultural difference between the UK and 
America, and China, China has already begun very serious 
human trial research.  
 
What will the insurance pay for? 
     According to the U.S. National Library of Medicine, 
health insurance plans in many cases will cover the costs 
of genetic testing when recommended or suggested by the 
person’s physician. Most insurance companies today will pay 
for at least some genetic counseling and genetic testing. 
An example of this is that under the Affordable Care Act, 
both genetic counseling and BRCA gene testing in females (a 
gene associated with breast cancer) is covered. There are 
differences in policies per provider when it comes down to 
which tests are covered, and many individuals opt out of 
having their insurance company paying for genetic testing. 
This is due to the fact that genetic tests can result in a 
person’s insurance coverage being effected. 
     However, the issue of insurance companies covering the 
costs of genetic modification is a different story. In the 
United States, there has been little-to-no discussion on 
the topic of coverage regarding genetic modification. In 
other countries, like the United Kingdom, there is at least 
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some discussion happening. However, in the United Kingdom, 
the discussion on insurance policy regarding genetic 
modification is focused mainly on the coverage issues 
regarding genetically modified products instead of the 
issues regarding the genetic modification of humans 
(James). Most likely, insurance companies will cover the 
cost of genetic modification for therapy and not 
enhancement. This aligns well with previous ethical and 
insurance policy decisions of the United States regarding 
the personal payment for cosmetic treatment that does not 
directly affect the person’s health, and the coverage of 
procedures directly related to health benefits. If someone 
decided to get facial reconstruction surgery because their 
cheekbones were too low for their liking, insurance would 
not pay for that procedure. In the same way, if a parent 
would like their child to be above-average in height, the 
funding for this genetic modification for enhancement would 
have to come out of their pocket and their insurance 
provider would not help cover the cost. On the other hand, 
if someone has a broken arm, their insurance provider would 
help cover the cost of the treatment for that patient. In 
the same way, if a parent had their future child’s genome 
sequences and was informed that they may have a genetic 
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disease, the insurance would help cover the cost for the 
genetic modification for therapy in that instance.  
 
How does this effect the impoverished of Appalachia? 
     If insurance companies in the United States follow by 
this precedent and genetic therapy is covered by insurance 
companies country-wide, Appalachians with health insurance 
will be able to benefit from the health-related aspects of 
the CRISPR-Cas9 system. However, the other modifications 
that are for the purpose of enhancement will be costly and 
will come out-of-pocket from expecting parents who would 
like to genetically enhance their child. Therefore, only 
wealthy individuals will have the ability to genetically 
enhance and design their children. Because of this, it is 
very likely that the poor of Appalachia will fall behind in 
things such as scholastics and athletics, because wealthier 
areas of the country would be able to afford genetic 
enhancement for the benefit of greater intelligence and 
physicality.  
 Additionally, the religious backbone of Appalachia may 
affect how parents feel about genetic modification. As more 
and more technology is discovered, there are more and more 
ways that parents can then neglect their children by 
withholding certain technologies from them(Hammond, 2010). 
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Hammond argues that in a range of cases, parents will have 
a moral obligation to use genetic treatments to prevent 
serious disabilities. However, this presents an issue if 
the parents cannot pay for this treatment. 
 
Ethical Stances Regarding Genetic Modification 
Thomas H. Murray  
     Thomas H. Murray’s “Stirring the ‘Designer Baby’ Pot” 
also ventures into the ethical dilemmas surrounding genetic 
manipulation for health and wellness versus genetic 
manipulation for enhancing traits that will not affect 
health whatsoever. He concludes that the ethical 
discussions about genetic manipulation cannot be postponed 
forever. He adds that in the future, “it would be a great 
public serve to provide a sober assessment of the choices 
that would-be parents increasingly face, and to encourage 
respectful dialogue about the meaning of parenthood and the 
worth of a child so that the parent and children can 
flourish together (Murray, 2014). This would help to 
prevent parents from making decisions like having genetic 
testing done for any other reason than for the best 
interest of the child. Still, no policy has been made 
regarding the allowance or distribution of modification or 
enhancement. However, trivial things like sex-selection are 
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still controversial and are debated on whether they are 
ethical or not. Regardless, “legislation, regulation, and 
professional guidelines depend on widely shared public 
values and their legitimacy” (Murray).  The public will 
have to decide what their priorities are regarding the 
genetic modification of future generations. 
 
David Resnik and Daniel Vorhaus 
Some views on genetic modification are strictly for or 
against the technology. David Resnik and Daniel Vorhaus 
break down the authenticity argument, uniqueness argument, 
freedom argument, and the giftedness argument and explain 
how each are unsound. They do so by explaining that each of 
these popular arguments assume a strong genetic 
determinism. Determinism is “usually equated with the 
problem of free will: we are compelled to make the choices 
that we make as a result of previous circumstances, and 
cannot make choices that are genuinely free.” Genetic 
determinism is defined as the view that genes cause traits. 
They argue this definition is not precise enough and 
therefore causes the other arguments against genetic 
modification to be false.  
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Michael J. Sandel  
In Michael J. Sandel’s “The Case Against Perfection: 
What’s Wrong with Designer Children, Bionic Athletes, and 
Genetic Engineering,” he argues that new breakthroughs in 
genetics present humanity with both a “problem and a 
predicament” (Sandel). The promise, he explains, is that 
someday there will be a way to prevent or cure a multitude 
of genetic diseases, and the predicament is the knowledge 
that genetic modification for purposes of advancing persons 
is possible with these newfound genetic technologies. 
Sandel concludes that the reason genetic modification makes 
individuals uneasy is because genetic manipulation 
threatens to eliminate mankind’s appreciation of life as 
what he says can only be described as a gift, and to leave 
“us with nothing to affirm… outside our own will” (Sandel).  
First, according to Sandel, there are four major areas 
that genetic manipulation would be used: muscles, memory, 
height, and sex selection. Other ethicists have approached 
genetic modification in a similar way. With each, he 
explains why it would be modified, what some claim is the 
reason for people’s unease, and a rebuttal as to why that 
is not the case. For example, Sandel describes reasons that 
gene therapy would be readily encouraged and accepted for 
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degenerative muscle diseases. However, when it comes to 
improving the musculature of unborn children, this could 
bring some concern to many individuals. “Why?” he asks. 
Many people explain their discomfort with the idea of 
improving or enhancing the muscle mass of embryos because 
they would grow into genetically enhanced athletes that 
would have a genetic advantage over other (non-genetically 
modified) individuals. They feel as if it would be unfair 
to persons who were not genetically enhanced prior to being 
born. Sandel rebuttals this claim by asserting that there 
is a fundamental flaw in that argument. He argues many 
successful athletes have natural genetic advantage over 
others by luck of the genetic draw. Some are naturally 
taller, have greater muscle mass, and were born with traits 
that allow them to be exemplary athletes. Consequently, he 
Sandel concludes people’s unease with genetic enhancement 
cannot stem from feelings of unfairness to those who are 
not genetically altered.   
He continues discussing each of the other three major 
areas for manipulation, describing how each causes unease 
but cannot be explained away by what most individuals would 
claim causes them to be uncomfortable with the idea of the 
manipulation. In regard to memory, he says that people are 
concerned that it would generate an unequal distribution of 
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enhancement, creating what could be considered two races of 
people. He claims that this argument is invalid because it 
ignores the moral question at hand: would the enhancement 
of certain persons’ memory dehumanize them, or would the 
poorer community of people that were not enhanced be put at 
an unfair disadvantage? The arguments are then similar in 
both height and sex selection: the claims of unease do not 
come from where most people assume. It must come from 
somewhere deeper than what it seems to on the surface.  
His conclusion is that this unease is sourced from the 
threat to our appreciation of life as something persons 
were given, not something that was controlled, and then  
‘because of this newfound control, persons would be left 
with nothing to affirm or behold that was any further than 
their own freewill.  
 
The Principles of Biomedical Ethics 
     The importance of biomedical ethics must be explored 
in order to begin to delve into the moral implications of 
genetic modification. Biomedical ethics must be involved in 
any scientific decision in order to regulate proceedings 
and protect individuals involved. Marcia Miki Sato’s “The 
influences of different socioeconomic scenarios in 
bioinformatics and biotechnology: The ethical issues 
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arising from technological advances,” marries 
bioinformatics and biotechnology to convey the importance 
of biomedical ethics within the two fields. She begins by 
explaining how that ethics in science becomes a complex 
issue, arguing that “Ethics should not be segregated into 
different fields as it assumes ideas of boundaries and 
stable values. However, science and society values are in 
constant transformations, which hinders the imposition of 
ethical values to science” (Sato, 2016).  
     She analyzes the public, private, and academic spheres 
in various situations regarding agriculture, genetic 
modification, genetic information, and biological research 
and addresses similar case studies of genetic information 
and explores how they were handled. Consistently, she 
supports the idea that “Ethics should not create obstacles 
to the scientific development, but to ensure that moral 
values are not deteriorated” (Sato). Biomedical ethics are 
to enhance the proceedings of scientific developments, 
helping each of them to be as successful as they can be 
while putting the least amount of risk on individuals or 
their surroundings. In the end, she concludes that “there 
is no binary way to answer bioethical issues” (Sato), but 
without an analysis of the consequences of the advances in 
biotechnology, the “essence of being human” (Sato) is at 
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risk. Although it would be easiest if biomedical ethical 
principles gave us straight forward answers, the decisions 
made regarding regulation and policy will most always be 
complex. However, the ethical decisions must be made in 
order to preserve our humanity. For this reason, a clear, 
concise, biomedical ethical policy regarding genetic 
modification is imperative. 
     It is appropriate to explore the principles of 
biomedical ethics to use as a guide for the construction of 
government regulations for the equal and fair distribution 
of genetic modification and manipulation with CRISPR-Cas9. 
The four principles, each of which being conditional, are 
as follows:  
1. The principle of respect for autonomy; this 
enforces the notion that medical professionals should 
not hinder the proficient implementation of the 
autonomy of the patient. Autonomy refers to a person’s 
ability to make their own choices in their lives, 
acting with stringency and self-will in their 
judgements. Another term for autonomy is “self-rule.” 
The ability of a person to be able to give their own 
medical consent has many qualifications—all of which 
could be strongly associated with the patient’s 
competency. If one cannot give consent, the patient’s 
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living will is consulted, or if there is no living 
will (especially in the case of genetically modified 
embryos) the surrogate decision maker is consulted (in 
the case of embryos, the parents).  
2. The principle of non-maleficence; this enforces 
the notion that medical professionals should not act 
in ways that would cause harm or discomfort to 
patients. The distinction between non-maleficence and 
the following principle is that non-maleficence can be 
met by doing nothing. An example of non-maleficence 
would be to not kill or cause unnecessary and 
unbeneficial pain.  
3. The principle of beneficence; this enforces the 
notion that medical professionals should act in ways 
that will benefit the wellbeing and health of the 
patient. This principle is different from non-
maleficence in that it requires action on the part of 
the participant. 
4. The principle of justice; this enforces the 
notion that health care and how that health care is 
payed for should be distributed in accordance with the 
demands of justice. (Degrazia, et.al, 2011)  
     These four principles should be used to shape the 
allocations for the just distribution of genetic 
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modification and manipulation along with the three ethical 
principles of prioritarianism, utilitarianism, and equality 
to create the fairest policy for all people. In using these 
principles in accordance with each other, any question of 
importance in each of them could be resolved quickly and 
effectively. Previously, it was stated that each of the 
principles are conditional and this stands true. One 
principle may out-weigh another in one situation and be 
equally important in another. This flexibility and 
adaptability allows for the specificity of each case as it 
presents itself.  
 
Other Ethical Principles 
The four principles of biomedical ethics can be used 
to shape the allocations for the just distribution of 
genetic modification and manipulation if paired with the 
three ethical principles of prioritarianism, 
utilitarianism, and equality. This would allow for the 
creation of the fairest policy for all individuals. In 
using these principles in accordance with each other, any 
question of importance in each of them could be resolved 
quickly and effectively. Previously, it was stated that 
each of the principles are conditional and this stands 
true. One principle may out-weigh another in one situation 
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and be equally important in another. This flexibility and 
adaptability allows for the specificity of each case as it 
presents itself.  
 
Prioritarianism 
The first, prioritarianism, is one of the moral 
principles that individuals argue is what must be followed 
to make fair and easy government regulations and  
allocations for the just distribution of treatments 
surrounding genetic manipulation and modification. 
Prioritarianism is a principle adjoining the ideas of 
favoring or having a preference for the individuals who are 
considered to be the worst-off. Examples of this would be 
to prioritize the sickest first which “aids those who are 
suffering right now; appeals to the ‘rule of rescue’” 
(Persad 260). Therefore, if someone from Appalachia was 
worse-off than someone in a wealthier area, the offspring 
in Appalachia would be taken care of first because of the 
beneficence and justice principles. This would help to 
distribute care ethically regardless of the economic status 
of the parents.  
However, some argue that the sickest people are the 
worst-off and therefore may benefit the least from 
treatment. For example, if someone had stage 4 cancer, 
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treating them may not be considered as ethical as treating 
a baby who has a better chance of surviving for a longer 
period of time. However, this is not the case with genetic 
modification. The sickest people in genetic modification 
are the offspring with the most genetic diseases or 
disabilities. If genetic modification is perfected, the 
sickest will benefit the most in this circumstance. The 
sickest would be individuals with fatal genetic diseases 
that would exterminate them either before they were born or 
soon afterwards.  
Additionally, by using the principles of biomedical 
ethics as a guide, the principle of beneficence enforces 
the notion that the medical professionals should help the 
sickest first in genetic situations because it will benefit 
the wellbeing and health of the patient.  
 
Utilitarianism 
To continue, utilitarianism is another of the moral 
principles that individuals argue is what must be followed 
in order to construct fair and simple government 
regulations and allocations for the just distribution of 
treatments surrounding genetic manipulation and 
modification. Utilitarianism is a principle surrounding the  
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ideas of maximizing the total benefits for all people. 
Examples of this would be to focus incentives on saving as 
many lives as possible which “[benefits] the greatest 
number; avoids the need for comparative judgements about 
quality or other aspects of lives” (Persad 260) and to 
focus incentives on “prognosis or life-years 
saved…[which]... maximizes life-years produced” (Persad 
260). 
Conversely, others argue that implementing an 
incentive that promotes saving as many lives as possible is 
“insufficient on its own” (Persad 269). If this principle 
is part of a larger group of incentives, including 
promoting the treatment of the sickest first, more people 
would be saved in a more ethical and just manner: infants 
who would have died before birth could live, while infants 
who would have lived to old age but gotten osteoporosis may 
not be put first on the list for service. In the same way, 
offspring that would be born with a genetic disease would 
be treated before another offspring that would be born with 
below-average height.  
Even others maintain that executing a motivation that 
promotes increasing life-years ignores the issue of 
distribution and quantity. As stated beforehand however, if 
this principle is part of a larger group of incentives, 
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including promoting the treatment of the sickest and worst-
off first, and promoting the saving of the most lives, more 
people would be treated appropriately according to the 
principles biomedical ethics.  Justice, non-maleficence, 
and beneficence are all maintained in these circumstances.  
 
Equality 
Finally, equality is one of the moral principles that 
individuals argue is what must be followed to create 
reasonable and simple government regulations  
and allocations for the evenhanded distribution of 
treatments surrounding genetic manipulation and 
modification. Equality is a principle surrounding the idea 
of treating all individuals alike, and placing everyone on 
level ground. An example of this would be to implement a 
lottery system where little information is needed about 
patients and any corruption is minimized in the system.  
Some argue that the lottery is blind to relevant 
factors. For example, “random decisions between someone who 
can gain 40 years and someone who can gain only 4 months” 
(Persad 267) are not appropriate decisions to make by 
lottery. Response: Again, if this principle is part of a 
larger group of incentives, including promoting the 
treatment of the sickest first, promoting the saving of the 
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most lives, and promoting the increasing of live-years, 
more people would be saved in a more efficient and fair 
manner.  
 Still, these are all situations in which all three 
principles, prioritarianism, utilitarianism, and equality 
all work together and promote each other. But what about in 
situations where they do not? What happens when two of the 
three conflict? One must look to the principles of 
biomedical ethics. Each of the four principles of 
biomedical ethics, respect for autonomy, beneficence, non-
maleficence, and justice can all act together as guides for 
what to do in each specific circumstance.   
For example, what would happen if all the parents of 
the offspring needing genetic modification were put into a 
lottery? The individuals chosen would not necessarily be 
the sickest or the worst-off. The individual may also not 
be in as severe a case as another embryo. Therefore, the 
principles of biomedical ethics would have to be in place 
in the lottery. It would somehow have to be separated by 
the sickest or worst-off, so the beneficence and non-
maleficence principles are included. In another example, 
there may be two equally bad cases of genetic disease. The 
order of treatment would have to be determined in another 
way other than promoting the life years or lives saved. 
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This is when a lottery could be used, to maintain the 
justice principle of biomedical ethics. This allows the 
distribution of care to be just, as it was randomly 
assigned by lottery so both cases had an equal chance of 
being treated first.  
All of this leads back to the beginning point, that 
without these principles, the poor of Appalachia would be 
left behind. Instead of the wealthiest of people enhancing 
their children to be taller, smarter, and more talented, 
only the sickest or worst-off of embryo would be treated in 
order of severity, not willingness or ability to pay.  
 
Conclusions 
Recent advances in biomedical technology have 
increased exponentially and therefore, great deal of 
ethical disputes that have introduced themselves into the 
scientific and medical communities. The just distribution 
of health care is still a highly-contested topic in the 
ethical and medical fields. In America, this problem 
infests the impoverished of the country.  
The lack of wealth in Appalachia results in an absence 
of proper health care for the citizens existing there. 
Government regulations such as implementing systems focused 
around utilitarianism, prioritarianism, and equality could 
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help to reverse this effect of poverty with the just 
distribution of genetic modification and manipulation, but 
the principles of biomedical ethics must contribute to the 
making of any policies or allocation system. Without the 
principles of respect for autonomy, beneficence, non-
maleficence, and justice, the three ethical principles 
previously stated cannot stand.  
In conclusion, government regulation or policy must be 
instated for the protection of all persons, including the 
underserved and impoverished of Appalachia. The lack of 
wealth in Appalachia results in an absence of proper 
healthcare for the citizens existing there. Government 
regulations such as implementing the principles of 
biomedical ethics must come to fruition sooner than later.  
Finally, without government regulation of the 
distribution of genetic modification and medical 
enhancements, the underprivileged of Appalachia will suffer 
immeasurably from the absence of protection against genetic 
ailments and disorders and absence of opportunity for 
genetic improvements and will eventually fall further 
behind more developed and wealthy areas concerning their 
health and quality of life. 
     Fortunately, great advances in science will continue 
to occur far into the future. Unfortunately, these advances 
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will be accompanied by new ethical problems that must be 
solved for the wellbeing of all persons. A great deal of 
ethical disputes that have introduced themselves into the 
scientific and medical communities will be followed by new 
ethical dilemmas. However, if policy can be instated now, 
it can act as a precedent for future policy, making the 
process to protect underserved persons and their 
surroundings much more efficient.  
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